Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.
Journal: Neurology and therapy
Published: July 10, 2024
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 02, 2024
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.
Journal: Therapeutic advances in neurological disorders
Published: June 14, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Journal: Neurology and therapy
Published: April 05, 2024
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
Journal: Journal of neurology
Published: December 19, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 31, 2023
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Journal: Neurology and therapy
Published: July 26, 2023
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Journal: Therapeutic advances in neurological disorders
Published: June 29, 2023
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 05, 2022
Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: January 26, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Journal: Advances in therapy
Published: November 19, 2021
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 12, 2021
Last Updated: 09/26/2026